Three-week hypofractionated radiotherapy in early glottic cancer-a single institution retrospective study
- PMID: 35919227
- PMCID: PMC9300409
- DOI: 10.3332/ecancer.2022.1381
Three-week hypofractionated radiotherapy in early glottic cancer-a single institution retrospective study
Abstract
Background: Radiotherapy is a standard treatment option for early glottic carcinoma (stage I and II) with a fraction size of 2-2.2 Gy over 5-7 weeks. This study evaluates the outcome and prognostic factors of a 3-week hypofractionated treatment in early glottic malignancy.
Materials and methods: The case records of 329 eligible patients with stage I and II glottic carcinoma recorded at the institution from 2003 to 2008 were retrospectively analysed. All patients were treated in a Cobalt-60 machine to a dose of 52.5 Gy in 15 fractions (3.5 Gy/fraction) over 3 weeks.
Results: Eighty-three percent had stage I disease. The local control rate at 5 years was 91.9%. On univariate analysis, stage I and II patients without subglottic extension had better local control. Disease extension to the subglottis fared poorly on multivariate analysis. After salvage treatment, the 5-year disease-free survival rate was 96.1% and the functional larynx preservation rate was 94.9% for stage I and 83.9% for stage II. The rate of severe complications was 2.1%.
Conclusion: Comparable results with low morbidity are achievable with a 3-week hypofractionation in early glottic cancers and it offers better patient convenience.
Highlights: In early glottic cancer, hypofractionated radiation provides excellent local control.Subglottic extension is a poor prognostic factor.5-year disease-free survival rate of 96.1%.5-year functional larynx preservation rate of 94.9%.Severe complication rate of 2.1%.
Keywords: glottic cancers; hypofractionation; radiotherapy.
© the authors; licensee ecancermedicalscience.
Conflict of interest statement
None of the authors have any conflict of interest in the publication of this manuscript.
Figures
Similar articles
-
Hypofractionated radiotherapy for T1N0M0 glottic cancer: retrospective analysis of two different cohorts of dose-fractionation schedules from a single institution.Clin Oncol (R Coll Radiol). 2012 Dec;24(10):e180-6. doi: 10.1016/j.clon.2012.07.001. Epub 2012 Aug 3. Clin Oncol (R Coll Radiol). 2012. PMID: 22862908
-
Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment?Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):322-8. doi: 10.1016/s0360-3016(02)03938-x. Int J Radiat Oncol Biol Phys. 2003. PMID: 12527044
-
Hypofractionated radiotherapy and surgery compared to standard radiotherapy in early glottic cancer.Am J Otolaryngol. 2020 Sep-Oct;41(5):102544. doi: 10.1016/j.amjoto.2020.102544. Epub 2020 May 15. Am J Otolaryngol. 2020. PMID: 32505989
-
3D conformal hypofractionated radical radiotherapy in early glottic cancer.Rep Pract Oncol Radiother. 2013 May 30;18(5):261-4. doi: 10.1016/j.rpor.2013.04.034. Rep Pract Oncol Radiother. 2013. PMID: 24416562 Free PMC article. Review.
-
[Early stages of laryngeal cancer (I-II stage) and therapeutic options: case report and review of literature].Acta Otorhinolaryngol Ital. 1996 Feb;16(1):40-6. Acta Otorhinolaryngol Ital. 1996. PMID: 8984839 Review. Italian.
Cited by
-
Outcome of T2 Glottic Cancer Treated with Radiotherapy Alone or Concurrent Chemo-Radiotherapy.Cancers (Basel). 2025 Feb 19;17(4):712. doi: 10.3390/cancers17040712. Cancers (Basel). 2025. PMID: 40002305 Free PMC article.
References
LinkOut - more resources
Full Text Sources